Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

Nature Communications

Volumn 6, Issue , 2015, Pages

  Stirzaker, Clare ^a,b   Zotenko, Elena ^a,b   Song, Jenny Z ^a   Qu, Wenjia ^a   Nair, Shalima S ^a,b   Locke, Warwick J ^a,b   Stone, Andrew ^a,b   Armstong, Nicola J ^a,c   Robinson, Mark D ^a,d   Dobrovic, Alexander ^e   Avery Kiejda, Kelly A ^f   Peters, Kate M ^g   French, Juliet D ^g,h   Stein, Sandra ^d   Korbie, Darren J ^g   Trau, Matt ^g   Forbes, John F ^f   Scott, Rodney J ^f,j   Brown, Melissa A ^g   Francis, Glenn D ^g,i   Clark, Susan J ^a,b   more..

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j JOHN HUNTER HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; METHYL CPG BINDING PROTEIN 2; TRANSCRIPTION FACTOR; WT1 PROTEIN;

CANCER; DATA SET; GENETICS; METHYLATION; TUMOR;

ARTICLE; BINDING SITE; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CONTROLLED STUDY; CPG ISLAND; DIFFERENTIALLY METHYLATED REGION; DNA ISOLATION; DNA METHYLATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PROMOTER REGION; TRIPLE NEGATIVE BREAST CANCER; EPIGENETICS; FEMALE; GENETICS; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

DNA METHYLATION; EPIGENOMICS; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84923090486     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6899     Document Type: Article

References (63)

1. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
2. Perou, C. M. Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1): 61-70 (2011).
3. Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
4. Dent, R. et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434 (2007).
5. Jatoi, I., Anderson,W. F., Jeong, J.-H. & Redmond, C. K. Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J. Clin. Oncol. 29, 2301-2304 (2011).
6. Park, Y. H. et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann. Oncol. 22, 1554-1560 (2011).
7. Reis-Filho, J. S. & Pusztai, L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378, 1812-1823 (2011).
8. Laird, P. W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253-266 (2003).
9. Szyf, M. DNA methylation signatures for breast cancer classification and prognosis. Genome Med. 4, 26 (2012).
10. Xu, Z. et al. Epigenome-wide association study of breast cancer using prospectively collected sister study samples. J. Natl Cancer Inst. 105, 694-700 (2013).
11. Chimonidou, M. et al. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin. Biochem. 46, 235-240 (2013).
12. Snell, C., Krypuy, M., Wong, E. M., Loughrey, M. B. & Dobrovic, A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 10, 12 (2008).
13. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
14. Holm, K. et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12, R36 (2010).
15. Fackler, M. J. et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71, 6195-6207 (2011).
16. Fang, F. et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3, 75ra25 (2011).
17. Cho, Y. H. et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res. Treat. 131, 197-205 (2012).
18. Stone, A. et al. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol. Cancer Ther. 12, 1874-1885 (2013).
19. Stefansson, O. A., Villanueva, A., Vidal, A., Marti, L. & Esteller, M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7, 1225-1229 (2012).
20. Serre, D., Lee, B. H. & Ting, A. H. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res. 38, 391-399 (2010).
21. Rauch, T. & Pfeifer, G. P. Methylated-CpG island recovery assay: A new technique for the rapid detection of methylated-CpG islands in cancer. Lab. Invest. 85, 1172-1180 (2005).
22. Nair, S. S. et al. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics 6, 34-44 (2011).
23. Robinson, M. D. et al. Evaluation of affinity-based genome-wide DNA methylation data: Effects of CpG density, amplification bias, and copy number variation. Genome Res. 20, 1719-1729 (2010).
24. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49 (2011).
25. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
26. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5, e13984 (2010).
27. Mehlen, P., Delloye-Bourgeois, C. & Chedotal, A. Novel roles for Slits and netrins: Axon guidance cues as anticancer targets? Nat. Rev. Cancer 11, 188-197 (2011).
28. Neufeld, G. & Kessler, O. The semaphorins: Versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8, 632-645 (2008).
29. Hughes, L. A. E. et al. The CpG island methylator phenotype: What's in a name? Cancer Res. 73, 5858-5868 (2013).
30. Matys, V. et al. TRANSFAC and its module TRANSCompel: Transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108-D110 (2006).
31. Yang, L., Han, Y., Suarez Saiz, F. & Minden, M. D. A tumor suppressor and oncogene: The WT1 story. Leukemia 21, 868-876 (2007).
32. Shen, H. & Laird Peter, W. Interplay between the Cancer Genome and Epigenome. Cell 153, 38-55 (2013).
33. Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: Patterns and paradigms. Nat. Rev. Genet. 10, 295-304 (2009).
34. Tommasi, S., Karm, D. L., Wu, X., Yen, Y. & Pfeifer, G. P. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res. 11, R14 (2009).
35. Pilato, B. et al. HOX gene methylation status analysis in patients with hereditary breast cancer. J. Hum. Genet. 58, 51-53 (2013).
36. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A. & Dwek, R. A. Glycosylation and the immune system. Science 291, 2370-2376 (2001).
37. Teschendorff, A., Miremadi, A., Pinder, S., Ellis, I. & Caldas, C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8, R157 (2007).
38. Yau, C. et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12, R85 (2010).
39. Kuo, W. H. et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: A clinical study of triple-negative breast carcinomas. PLoS ONE 7, e45831 (2012).
40. Rody, A. et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 13, R97 (2011).
41. Hallett, R. M., Dvorkin-Gheva, A., Bane, A. & Hassell, J. A. A gene signature for predicting outcome in patients with basal-like breast cancer. Sci. Rep. 2, 227 (2012).
42. Sproul, D. et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc. Natl Acad. Sci. USA 108, 4364-4369 (2011).
43. Cheng, Y. et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res. 70, 6516-6526 (2010).
44. Lleras, R. A. et al. Hypermethylation of a cluster of Krüppel-Type zinc finger protein genes on chromosome 19q13 in oropharyngeal squamous cell carcinoma. Am. J. Pathol. 178, 1965-1974 (2011).
45. Huang, R.-L. et al. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS ONE 7, e41060 (2012).
46. Severson, P. L., Tokar, E. J., Vrba, L., Waalkes, M. P. & Futscher, B. W. Coordinate H3K9 and DNA methylation silencing of ZNFs in toxicant-induced malignant transformation. Epigenetics 8, 1080-1088 (2013).
47. Vanaja, D. K., Cheville, J. C., Iturria, S. J. & Young, C. Y. F. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877-3882 (2003).
48. Reinert, T. et al. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS ONE 7, e46297 (2012).
49. Rodriguez, B. A. et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 29, 1459-1465 (2008).
50. Bruno, P. et al. WT1 CpG islands methylation in human lung cancer: A pilot study. Biochem. Biophys. Res. Commun. 426, 306-309 (2012).
51. Ghoshal, K. et al. HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS ONE 5, e10338 (2010).
52. Okuda, H. et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25, 1733-1742 (2006).
53. Miyoshi, Y. et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin. Cancer Res. 8, 1167-1171 (2002).
54. Moorwood, K. et al. Antisense WT1 transcription parallels sense mRNA and protein expression in fetal kidney and can elevate protein levels in vitro. J. Pathol. 185, 352-359 (1998).
55. Dallosso, A. R. et al. Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. RNA 13, 2287-2299 (2007).
56. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
57. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
58. Coolen, M. W., Statham, A. L., Gardiner-Garden, M. & Clark, S. J. Genomic profiling of CpG methylation and allelic specificity using quantitative highthroughput mass spectrometry: Critical evaluation and improvements. Nucleic Acids Res. 35, e119 (2007).
59. Clark, S. J., Harrison, J., Paul, C. L. & Frommer, M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22, 2990-2997 (1994).
60. Du, P. et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
61. Kuhn, M. Building predictive models in R using the caret Package. J. Stat. Softw. 28, 1-26 (2008).
62. Mevik, B.-H. & Wehrens, R. The pls Package: Principal component and partial least squares regression in R. J. Stat. Softw. 18, 1-24 (2007).
63. Tamayo, S. M. P., Mesirov, J. & Golub, T. Consensus clustering: A resamplingbased method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91-118 (2003).